Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mpo.2950020411 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
l-Asparaginase Immobilized on Nanographene Oxide as an Efficient Nanobiocatalytic Tool for Asparagine Depletion in Leukemia Cells.
Bioconjug Chem
January 2025
Department of Biochemistry, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University in Torun, ul. Lwowska 1, 87-100 Torun, Poland.
l-Asparaginase (l-ASNase) catalyzes the hydrolysis of l-asparagine, leading to its depletion and subsequent effects on the cellular proliferation and survival. In contrast to normal cells, malignant cells that lack asparagine synthase are extremely susceptible to asparagine deficiency. l-ASNase has been successfully employed in treating pediatric leukemias and non-Hodgkin lymphomas; however, its usage in adult patients and other types of cancer is limited due to significant side effects and drug resistance.
View Article and Find Full Text PDFA human-like glutaminase-free asparaginase is highly efficacious in ASNS leukemia and solid cancer mouse xenograft models.
Cancer Lett
December 2024
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, USA; Enzyme By Design Inc., Chicago, USA; Research Biologist, Biological Science Research and Development, Department of Veterans Affairs Medical Center, Chicago, IL, USA. Electronic address:
L-asparaginase (L-ASNase) is crucial in treating pediatric acute lymphoblastic leukemia (ALL), but its use is hampered by side effects from the immunogenicity and L-glutaminase (L-GLNase) co-activity of FDA-approved bacterial L-ASNases, often leading to treatment discontinuation and poor outcomes. The toxicity of these L-ASNases makes them especially challenging to use in adult cancer patients. To overcome these issues, we developed EBD-200, a humanized guinea pig L-ASNase with low Km and no L-GLNase activity, eliminating glutamine-related toxicity.
View Article and Find Full Text PDFCalaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia.
Int J Mol Sci
December 2024
Department of Medical Oncology, Cancer Institute, West Virginia University, Morgantown, WV 26506, USA.
Our previous studies have demonstrated that pegcrisantaspase (PegC), a long-acting asparaginase, synergizes with the BCL-2 inhibitor Venetoclax (Ven) in vitro and in vivo; however, the anti-leukemic activity of -derived asparaginases in combination with BCL-2 inhibition, and potential synergy with inhibitors of MCL-1, a key resistance factor of BCL-2 inhibition, has yet to be determined. Using a combination of human AML cells lines, primary samples, and in vivo xenograft mouse models, we established the anti-leukemic activity of the BCL-2 inhibitor S55746 and the MCL-1 inhibitor S63845, alone and in combination with the long-acting asparaginase calaspargase pegol-mknl (CalPegA). We report that CalPegA enhances the anti-leukemic effect of S55746 but does not impact the activity of S63845.
View Article and Find Full Text PDFEnhancing the Stability and Anticancer Activity of Asparaginase Through Nanoparticle Immobilization: A Biotechnological Perspective on Nano Chitosan.
Polymers (Basel)
November 2024
Department of Biology, Faculty of Science, Al-Baha University, Al-Baha 65525, Saudi Arabia.
There is a shortage in the experimental research directly comparing the effectiveness of different nanoparticles in boosting asparaginase (ASNase) activity. This study assessed the impact of various nanoparticles on enhancing ASNase activity, stability, and anticancer effects through immobilization. ASNase was immobilized on different nanoparticles, and its efficiency was measured.
View Article and Find Full Text PDFEfficacy and Safety Profile of Biosimilar Polyethylene Glycol (PEG)-Asparaginase (Asviia) in Patients With Acute Leukemia: A Retrospective Study From Kashmir.
Cureus
November 2024
Medical Affairs, Zydus Lifesciences LTD, Ahmedabad, IND.
Background: Biosimilar pegylated L-asparaginase offers a promising alternative to the innovator molecule for treating acute lymphoblastic leukemia (ALL) in Indian children. It addresses challenges associated with drug availability and cost while providing similar therapeutic advantages. This biosimilar ensures wider access to essential treatment in resource-limited settings such as India.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!